date:May 23, 2012
dequate directions for use. In a follow-up January 2012 inspection, the FDA found that Crescendo was still distributing HybriSil, despite the warnings.
This action was taken because Crescendo Therapeutics continued to sell unapproved new products, said Dara A. Corrigan, the FDAs associate commissioner for regulatory affairs. The FDA continues to be committed to protecting consumers against new drug products marketed without FDA approval.
There are many other topical corticosteroids approved